Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy

Objective To assess cure fraction and conditional survival probabilities for oncological outcomes in patients with T1 high-grade (T1HG) non-muscle-invasive bladder carcinoma (NMIBC) treated with adequate Bacillus Calmette-Gu & eacute;rin (BCG) immunotherapy.Patients and Methods This multi-instit...

Descripción completa

Detalles Bibliográficos
Autores: Subiela, JD, de la Parra, I, Taborda, J, Medina, AA, Pichler, R, Krajewski, W, Ojeda, CM, Mardomingo, AF, Durán, PD, Pérez, EL, González-Padilla, DA, Aumatell, J, Mori, K, Scilipoti, P, Longoni, M, de Angelis, M, Caño-Velasco, J, Puentedura, AL, Pujol, LP, Contieri, R, Gallioli, A, Tukiendorf, A, D'Andrea, D, Teoh, JY, Afferi, L, Del Giudice, F, Marcq, G, Albisinni, S, Soria, F, Mertens, LS, Laukhtina, E, Tully, K, Mari, A, Guerrero-Ramos, F, Alvarez-Maestro, M, Martín, CC, Melendres, FA, Buisan, O, López-González, JA, Dominguez-Escrig, JL, Aranda, J, Elena, JLR, Basile, G, Santos, VGD, Moschini, M, Pradere, B, Acosta, EA, Palacio, FL, Puig, AC, Gajate, P, Saiz, A, Gontero, P, Revilla, FJB
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p21048
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21048
Access Level:acceso abierto
Palabra clave:non-muscle-invasive bladder cancer
BCG immunotherapy
recurrence
progression
cure fraction
Descripción
Sumario:Objective To assess cure fraction and conditional survival probabilities for oncological outcomes in patients with T1 high-grade (T1HG) non-muscle-invasive bladder carcinoma (NMIBC) treated with adequate Bacillus Calmette-Gu & eacute;rin (BCG) immunotherapy.Patients and Methods This multi-institutional retrospective cohort study included 1403 patients with T1HG NMIBC treated between 2007 and 2020, adhering to modern guidelines including mandatory second transurethral resection of bladder tumour and adequate BCG, defined as at least five of six induction doses and at least two of three maintenance doses. Cure fraction, defined as the proportion of patients who will never experience the event of interest, was calculated for recurrence-free survival (RFS), progression-free survival (PFS), cancer-specific survival (CSS) and overall survival (OS) using a mixture cure model. Conditional survival probabilities over 5 years were also computed.Results Cure fractions were 41% (95% confidence interval [CI] 36%-46%) for RFS, 71% (95% CI 65%-76%) for PFS, 76% (95% CI 70%-83%) for CSS, and 38% (95% CI 28%-49%) for OS. Patients in very-high-risk subgroups, according to the European Association of Urology risk stratification, showed significantly lower cure fractions, particularly for PFS (61% [95% CI 50%-72%]) and CSS (59% [95% CI 34-84%]). Conditional survival analysis demonstrated that patient prognoses improved over time, with 5-year conditional RFS, PFS, CSS and OS probabilities exceeding 90% for patients who were event-free at 5 years from diagnosis.Conclusions We found that BCG immunotherapy achieves a statistical cure in select T1HG NMIBC patients, with avoidance of progression to muscle-invasive bladder carcinoma in approximately 70% of cases. The probability of experiencing any adverse oncological event (recurrence, progression or death) is less than 10% among patients who remain event-free for 5 years.

Similares en LA Referencia